APA (7th ed.) Citation

Kremer, J. M., Bingham, C. O., Cappelli, L. C., Greenberg, J. D., Madsen, A. M., Geier, J., . . . Kavanaugh, A. (2021). Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry. ACR open rheumatology, 3(3), 173-184. https://doi.org/10.1002/acr2.11232

Chicago Style (17th ed.) Citation

Kremer, Joel M., et al. "Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry." ACR Open Rheumatology 3, no. 3 (2021): 173-184. https://doi.org/10.1002/acr2.11232.

MLA (9th ed.) Citation

Kremer, Joel M., et al. "Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry." ACR Open Rheumatology, vol. 3, no. 3, 2021, pp. 173-184, https://doi.org/10.1002/acr2.11232.